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Abstract
Although it is well known that epidermal growth factor receptor (EGFR) is involved in lung cancer progression, whether
EGFR contributes to lung epithelial cell transformation is less clear. Mucin 1 (MUC1 in human and Muc1 in animals), a
glycoprotein component of airway mucus, is overexpressed in lung tumors; however, its role and underlying mechanisms in
early stage lung carcinogenesis is still elusive. This study provides strong evidence demonstrating that EGFR and MUC1 are
involved in bronchial epithelial cell transformation. Knockdown of MUC1 expression significantly reduced transformation of
immortalized human bronchial epithelial cells induced by benzo[a]pyrene diol epoxide (BPDE), the active form of the
cigarette smoke (CS) carcinogen benzo(a)pyrene (BaP)s. BPDE exposure robustly activated a pathway consisting of EGFR,
Akt and ERK, and blocking this pathway significantly increased BPDE-induced cell death and inhibited cell transformation.
Suppression of MUC1 expression resulted in EGFR destabilization and inhibition of the BPDE-induced activation of Akt and
ERK and increase of cytotoxicity. These results strongly suggest an important role for EGFR in BPDE-induced transformation,
and substantiate that MUC1 is involved in lung cancer development, at least partly through mediating carcinogen-induced
activation of the EGFR-mediated cell survival pathway that facilitates cell transformation.
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Introduction
Lung cancer is a major health concern, afflicting approximately
160,000 people each year in the United States [1,2]. Most lung
cancers are associated with mainstream or sidestream cigarette
smoke (CS). Carcinogens derived from CS such as benzo(a)pyrene
(BaP) induce lung cancer through DNA damage. Because of
activation of DNA repair pathways that remove genomic lesions
and apoptosis that eliminates cells with extensive genetic damage,
only a small fraction of cells acquiring DNA damage become
malignant. Therefore, cancer development and progression likely
depend on the balance between cell survival and apoptosis signals,
both of which are activated by carcinogens and environmental
factors. The pathways controlling survival include mitogen-activated
protein kinases (MAPK), Akt and NF-kB [3,4,5]. Although we have
learned a great deal about the tumor-promoting role of survival
signaling, how CS activates these pathways in lung cancer initiation
and progression remains poorly understood. Thus, delineating the
mechanisms underlying the influences of survival signaling on cell
transformation and tumor development could identify novel
intervention targets for prevention and therapy for lung cancer.
Aberrant epidermal growth factor receptor (EGFR) activation is
involved in cancer progression [6,7,8]. Lung cancer cells acquire
dependence on EGFR activity for survival, substantiating the use
of EGFR inhibitors for lung cancer therapy [9,10]. The ligands for
EGFR including EGF and transforming growth factor a (TGFa)
bind EGFR, triggering EGFR dimerization and autophosphory-
lation. The autophosphorylated C-terminal tyrosine kinase domain
of EGFR in the cytoplasm initiates a cascade of intracellular
signaling pathways [12] [11,12,13]. The EGFR downstream
signaling pathways include components of the Ras/Raf/MAPK
(ERK, JNK and p38) and PI3K/Akt, of which ERK and Akt
are two main kinases for EGFR-mediated cell survival and
proliferation. The EGFR signaling is terminated by endocytosis
of the phosphorylated receptor–ligand complex followed by
proteasomal degradation of EGFR [12]. How EGFR is
activated by carcinogen in lung epithelial cells and whether
EGFR is required for lung epithelial transformation is not well
understood. In a breast cancer mouse model, mucin 1 (MUC1
for human and Muc1 for nonhuman species) facilitated TGFa-
induced EGFR activation and breast cancer development
[14,15]. Therefore, it is interesting to determine if MUC1 is
also involved in carcinogen-induced EGFR activation for lung
cancer development.
As a mucin family protein expressed on the bronchial epithelial
cell membrane, MUC1 is induced during airway inflammation
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during respiratory tract infection [16,17,18,19]. During chronic
inflammation, MUC1 expression is sustained at a high level,
which may contribute to cancerd e v e l o p m e n t[ 2 0 ] .M U C 1h a s
two subunits that are coded by a single gene: the N-terminal
subunit containing highly conserved repeats of 20 amino acids
that are modified by O-glycosylation and the transmembrane C-
terminal subunit containing 72 amino acids residues that binds
to various proteins involved in signal transduction [20,21].
MUC1 is regarded as a tumor antigen because it is aberrantly
overexpressed in various cancers including lung cancer, and
immunotherapy with anti-MUC1 antibodies showed substantial
anticancer effect against prostate and breast cancers [16].
Although artificial overexpression of MUC1 triggers fibroblast
cell transformation, the mechanism for this process is poorly
understood [22]. While MUC1 interacts with a variety of cellular
factors, recent studies have suggested functional interactions
between MUC1 and EGFR-mediated survival signaling
[14,15,20,23,24]. Interestingly, MUC1 expression levels were
reported to be associated with response to EGFR inhibitors in
lung cancer patients [25]. In non-small cell lung cancer, MUC1
is expressed in a depolarized pattern and correlated with poor
patient survival [26]. Although it is known that MUC1 is
involved in lung cancer progression particularly in metastasis
and MUC1 is regarded as target for lung cancer therapy
[16,25,27,28], whether and how MUC1 contributes to CS-
induced lung cancer initiation, particularly in lung epithelial cell
transformation has not been well elucidated.
The goal of this study was to investigate the role and underlying
mechanisms of MUC1 bronchial epithelial transformation. The
results show that MUC1 contributes to the CS-specific carcinogen
benzo(a)pyrene diol epoxide (BPDE)-induced human epithelial
cell transformation through facilitating a cell survival pathway
consisting of EGFR, Akt and ERK, highlighting that MUC1 and
EGFR could be molecular targets for lung cancer prevention.
Materials and Methods
Reagents
BPDE was obtained from NCI Chemical Carcinogen Reference
Standards Repository, Midwest Research Institute. Cycloheximide
was purchased from Sigma. EGFR inhibitor II (a selective and
irreversible inhibitor that blocks EGFR autophosphorylation),
LY294002, U0126, and SP600125 were purchased from Calbio-
chem. Small interfering RNA (siRNA; SiGenome SMARTpool)
for MUC1, EGFR and negative control siRNA were purchased
from Dharmacon. The following primary antibodies were used for
Western blot: anti-Mucin 1 (GP1.4, Santa Cruz), anti-b-Tubulin
and -b-Actin (Sigma-Aldrich); and anti-phospho-EGFR (Y1086,
Abcam), and anti-EGFR, -ERK, -Akt and -phospho-Akt (Ser473)
(Cell Signaling Technology); anti-phospho-ERK (Y185/187)
(Biosource). Filters collected from the AMESA Type 1300 smoking
machine, which generated mainstream CS, were used to prepare
cigarette smoke extract (CSE) by sequentially extracting materials
from with culture medium (for dissolving water-soluble compo-
nents) and DMSO (for dissolving water-insoluble components).
The water-soluble and -insoluble fractions were mixed to make the
total CSE before use. Total particulate material (TPM) was
determined by weighing the filter before and after extraction. The
MUC1 shRNA plasmid was constructed by inserting a synthetic
oligonucleotide encoding a hairpin sequence with a 19-nucleotide
stem that is homologous to the target sequence of human MUC1,
CCGGGATACCTACCATCCTAT, and a 9-base loop sequence
into pSilencer (Oligoengine, Seattle, WA).
Cell Culture
BEAS-2B cells were obtained from American Type Culture
Collection (ATCC) (Manassas, VA). The immortalized human
bronchial epithelial cells, HBEC-2, were generously provided by
Drs. Shay and Minna, Southwestern Medical Center, Dallas, TX
[29]. BEAS-2B and HBEC cells were maintained in Keratinocyte
serum free medium (KSFM) (Invitrogen), supplemented with
5 mg/L of human recombinant EGF and 50 mg/L of bovine
pituitary extract in plates coated with fibronectin (Athena ES). The
lung cancer cell lines (H23, A549, H460, H1299, H2009 and
H1568) obtained from ATCC (Manassas, VA) were cultured in
RPMI 1640 supplemented with 10% fetal bovine serum (FBS),
1 mM of glutamine, 100 U/ml of penicillin, and 100 mg/ml of
streptomycin. Monolayer cultures were incubated at 37uCi na
95% humidified atmosphere containing 5% CO2.
Soft agar assay
BEAS-2B cells were treated with BPDE (0.1 mM) every two days
for a total of 3 treatments. For each treatment, the cells were
exposed to BPDE for 1 h followed by incubation in fresh medium.
The cells (1610
4/well, 12-well plates) were then seeded in soft
agar for colony formation. Colonies in the agar were photo-
graphed and counted after 2 wk incubation. HBEC-2 cells were
treated similarly as that of BEAS-2B cells with CSE (10 mg/ml
TPM) or BPDE (0.1 mM) weekly (1 hr each time) for 12 wk;
colonies were counted after 3 wk incubation [30]. The average
number of colonies 6 S.D. was determined using 6 randomly
selected fields. All experiments were run in triplicate.
Transfections
BEAS-2B cells were seeded in a 6-well plate at ,50%
confluency. After overnight culture, cells were transfected with
small interfering RNA (siRNA) with INTERFERin
TM siRNA
transfection reagent (Polyplus-transfection) according to manufac-
turer’s instructions. Forty-eight hours after transfection, MUC-1,
EGFR, Akt and ERK protein levels were determined by Western
blot. For stable shRNA transfection, cells were transfected with
MUC1 shRNA at 30,50% confluency using FuGENE HD
transfection reagent (Roche) following the manufacturer’s instruc-
tions. Clones stably expressing MUC1 knockdown were selected
with puromycin (1 mg/ml) and identified by Western blot.
Western Blot
Cells were harvested and total cell protein was extracted in M2
buffer (20 mM Tris-HCl, pH 7.6, 0.5% Nonidet P-40, 250 mM
NaCl, 3 mM EDTA, 3 mM EGTA, 2 mM dithiothreitol, 0.5 mM
phenylmethylsulfonyl fluoride, 20 mM-glycerophosphate, 1 mM
sodium vanadate, and 1 mg/ml leupeptin). Equal amounts of cell
proteins were resolved in 12% SDS-polyacrylamide gels and then
transferred to PVDF membranes. The proteins were visualized by
enhanced chemiluminescent detection reagent according to the
manufacturer’s instructions (Millipore).
Cytotoxicity Assay
Cytotoxicity was assessed using a 3-(4,5-dimethylthiazolyl-2-)-
2,5-diphenyltetrazolium bromide (MTT) cell proliferation assay
and a lactate dehydrogenase (LDH) release-base cytotoxicity
detection kit (Promega) [31]. Cells were seeded in 48-well plates at
,70% confluency, cultured overnight, and then treated as
indicated in the figure legends. Cell viability was determined
using MTT assay. The percentage of viable cells was calculated
using the following formula: Cell viability (%)=(Absorbance of
treated sample/Absorbance of control)6100. Cell death based on
MUC1 Facilitates HBEC Cell Transformation
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(%)=[(Experimental value-Spontaneous LDH release)/(Maxi-
mum LDH-Spontaneous LDH release)] 6100 [32].
Statistics
All data were expressed as mean 6 S.D. Statistical significance
was examined by one-way analysis of variance. In all analyses,
p,0.05 was considered statistically significant.
Results
MUC1 suppression inhibits BPDE-induced human
bronchial cell transformation
Cell transformation, the transition of normal to cancerous cells,
is a critical early process for cancer initiation. To investigate if
MUC1 plays a role in bronchial epithelial cell transformation,
MUC1 was knocked down by RNA interference in BEAS-2B, an
immortalized human bronchial epithelial cell line that is sensitive
to carcinogen-induced transformation in vitro [33]. The cells were
treated with BPDE (0.1 mM) for 1 wk and then plated in soft agar
for colony formation. Remarkably, transient knockdown of
MUC1 expression strikingly reduced BPDE-induced colony
formation. The negative control siRNA did not affect on
BPDE-induced transformation (Figs. 1A, 1B). To exclude
potential off-target effect of siRNA, this observation was validated
by stably knocking down MUC1 expression in BEAS-2B cells
with a MUC1 shRNA targeting different site in the MUC1
messenger RNA. A dramatic reduction of BPDE-induced colony
formation was seen in cells transfected with MUC1 shRNA, but
not the negative shRNA (Figs. S1). These results suggest that
MUC1 plays a significant role in promoting BPDE-induced
bronchial epithelial cell transformation.
BPDE induces EGFR-mediated Akt and ERK activation
To investigate the underlying mechanism by which MUC1
potentiates BPDE-induced bronchial epithelial cell transformation,
we focused on the activation of the EGFR pathway because this
pathway can be activated by benzo(a)pyrene and MUC1 was
reported to modulate EGFR activation in breast epithelial cells
[34,35]. HBEC-2 and BEAS-2B cells were treated with BPDE for
2 h and activation of EGFR was detected with an antibody
recognizing EGFR phosphorylated at tyrosine 1068. BPDE
activated EGFR in a dose-dependent manner, starting at a
concentration of 0.05 mM (Fig. 2A). Akt and ERK, two major
downstream kinases of EGFR, were activated by BPDE in a
similar manner (Fig. 2A). Supporting this observation, cigarette
smoke extract (CSE) activated EGFR, Akt and ERK in HBEC-2,
starting 15 min and persisting over 2 h after treatment (Fig. S2A).
Because Akt and ERK are activated by a variety of pathways other
than EGFR, we examined if BPDE-induced Akt and ERK
activation is mediated by EGFR by knocking down the expression
of EGFR with EGFR siRNA. While the negative control siRNA
had a marginal effect on BPDE-induced activation of Akt and
ERK, the EGFR siRNA, which effectively eliminated EGFR
expression, completely blocked BPDE-induced Akt and ERK
activation (Fig. 2B). Consistently, the EGFR inhibitor, which
effectively suppressed BPDE-induced EGFR activation, effectively
attenuated BPDE-induced Akt and ERK activation (Fig. 2C).
Neither EGFR siRNA nor the EGFR inhibitor inhibited the
expression of MUC1 (Figs. 2B, 2C), suggesting that it is unlikely
that MUC1 functions downstream of EGFR for BPDE-induced
Akt and ERK activation. Altogether, these results strongly suggest
that BPDE activates EGFR, which in turn, mediates activation of
Akt and ERK pathways in bronchial epithelial cells.
Because transformation of HBEC-2 is a slow process that takes
up to 12 wk [30,36], we then examined if chronic exposure to a
non-cytotoxic concentration of BPDE that induces transformation
results in EGFR activation. Cells were treated weekly with BPDE
(0.1 mM) for up to 12 wk and activation of EGFR, Akt and ERK
was detected by Western blot. Activation of EGFR was first
detected 4 wk post treatment, gradually increased and peaked
after 8 wk and was sustained at 12 wk (Fig. 3A). A similar trend of
activation of Akt and ERK was also observed. EGFR, Akt and
ERK activation was detected in the cells after several passages,
suggesting a sustained constitutive activation of EGFR-mediated
pathways. Interestingly, the expression level of MUC1 is also
induced at 4 wk and gradually increased through 12 wk (Fig. 3A).
Consistent with the results from BPDE treatment, chronic CSE
exposure similarly activated EGFR, Akt and ERK activation,
which was also associated with increased MUC1 expression (Fig.
S2B). These results suggest that chronic exposure to BPDE results
in constitutive activation of EGFR, Akt, and ERK, which is
associated with increased expression of MUC1 in HBEC-2 cells.
To further substantiate the finding that EGFR is activated during
transformation, we examined this pathway in precancerous cells
HBEC-2B, which were derived from colonies that formed in soft
agar after chronic BPDE exposure [30,36]. Although these cells
were unable to form tumors in nude mice [30,36], they readily
form colonies in soft agar (Fig. 3B). In these cells, EGFR, Akt and
ERK were constitutively activated in association with MUC1
Figure 1. Suppression of MUC1 inhibits BPDE-induced transformation in BEAS-2B cells. A, BEAS-2B cells were transfected with MUC1
siRNA or negative control siRNA. The cells were then treated with BPDE (0.1 mM) for 1 wk and seeded in soft agar. Colony formation was
photographed under a light microscope. B, Quantitative representation of the transformation experiment. Bars show the averages of colony numbers
of 6 randomly selected fields. Data shown are mean 6 S.D; ** P,0.01. Insert, Confirmation of MUC1 knockdown by Western blot.
doi:10.1371/journal.pone.0033846.g001
MUC1 Facilitates HBEC Cell Transformation
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e33846overexpression (Fig. 3C). The association of MUC1 expression
and EGFR activation suggests that MUC1 plays a role in BPDE-
induced EGFR activation and cell transformation.
EGFR-mediated Akt and ERK activation protects cells
against BPDE-induced cytotoxicity
Because survival of cells with genetic mutations is essential for
cancer initiation and Akt and ERK are well known survival
signals, we next investigated if BPDE-induced and EGFR-
mediated Akt and ERK activationp r o t e c t sc e l l sf r o mB P D E -
induced cytotoxicity. Pharmacological inhibitors blocking each
pathway were followed by treatment with BPDE at a
concentration (0.2 mM) that induced moderate cell death.
Under this condition, BPDE caused ,20% cell death that
was detected by LDH release and MTT assays. While the
EGFR inhibitor alone was slightly toxic, it dramatically
increased cell death. Coordinately, the PI3 kinase (PI3K)/Akt
inhibitor LY294002 effectively potentiated BPDE-induced
cytotoxicity. Surprisingly, the MEK/ERK inhibitor U0126
had only a slight sensitization to BPDE-induced cell death. As
a control, the JNK inhibitor SP600125 had little effect on
BPDE’s cytotoxicity (Fig. 4A, 4B). All the inhibitors were
effective in blocking their respective pathways (data not shown)
[37]. These results suggest EGFR-mediated pathways, particu-
larly Akt, play important roles in protecting bronchial epithelial
cells against BPDE-induced cell death, which may contribute to
lung cancer development.
Suppression of EGFR, Akt and ERK activation inhibits
BPDE-induced cell transformation
Next, we assessed the role of EGFR, Akt and ERK in BPDE-
induced cellular transformation. BEAS-2B cells were treated with
BPDE (0.1 mM), with or without inhibitors against each pathway
for 1 wk, and then plated in soft agar for colonies formation. As
expected, inhibition of EGFR and Akt effectively suppressed
BPDE-induced colonies formation. Surprisingly, the ERK inhib-
itor U0126, which only slightly increased BPDE’s cytotoxicity,
effectively blocked BPDE-induced transformation (Fig. 5A, 5B).
This observation suggests that ERK contributes to cell transfor-
mation by a mechanism other than cell survival. Nevertheless,
these results suggest that activation of EGFR, Akt and ERK is
required for transforming human bronchial epithelial cells.
MUC1 is required for EGFR stabilization and
BPDE-induced EGFR, Akt and ERK activation
Because BPDE stimulated EGFR-mediated Akt and ERK
activation that was associated with MUC1 overexpression
(Figs. 3A, 3C) and MUC1 modulates EGFR activation in breast
epithelial cells [34,35], we examined if MUC1 is involved in
BPDE-induced activation of EGFR-mediated Akt and ERK
Figure 2. Transient BPDE exposure activates Akt and ERK through EGFR in human bronchial epithelial cells. A, Acute BPDE exposure
induces activation of EGFR, Akt, and ERK in BEAS-2B cells. BEAS-2B cells were treated with the indicated concentrations of BPDE for 2 hr. Activation of
EGFR, Akt and ERK were detected by Western blot with antibodies recognizing each phosphorylated protein (phosphorylation sites are indicated). b-
Actin was detected as an input control. B, Suppression of EGFR attenuates the activation of Akt and ERK in BEAS-2B cells. The expression and activity
of EGFR in BEAS-2B cells were suppressed with either EGFR inhibitor III or EGFR siRNA. The cells were then exposed to BPDE (0.4 mM) for 2 hr. The
indicated proteins were detected by Western blot. b-Actin was detected as a loading control.
doi:10.1371/journal.pone.0033846.g002
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compared to the cells stably transfected with a negative shRNA
vector with respect to BPDE-induced EGFR, Akt and ERK
activation. Although the phosphorylation of EGFR, Akt and ERK
was substantially activated by BPDE in the control cells, MUC1
knockdown completely attenuated BPDE-induced activation of
these pathways (Fig. 6A). These results strongly suggest that
MUC1 is required for BPDE-induced activation of EGFR, Akt
and ERK in bronchial epithelial cells. It is worthy noting that the
basal pERK was remarkably higher in the MUC1 knockdown
cells and the extent of suppression of BPDE-induced ERK
activation was lower than that of Akt. This may be explained by
the complexity of ERK activation in cells and other pathway(s)
may compensate the suppression of EGFR-mediated ERK
activation.
It was noticed that the expression of EGFR protein was reduced
in the MUC1 knockdown cells (Fig. 6A). However, the EGFR
message RNA expression levels were comparable between the cells
with or without MUC1 knockdown (Fig. 6B). Therefore, we
examined if the stability of EGFR is regulated by MUC1. Protein
synthesis was shut off with cycloheximide and MUC1 expression
was monitored for up to 3 hr. The half-life of EGFR in the
MUC1-suppressed cells was ,32 min, much shorter than that of
the negative control shRNA transfected cells (,145 min) (Fig. 6B).
The mechanism of EGFR degradation is complex, which involves
a pathway involving both lysosome and proteasome [38].
Consistently, the proteasome inhibitor MG132 and lysosome
inhibitor chloroquine alone or in combination eliminated the
EGFR expression difference between the MUC1 knockdown and
control cells (Fig. S3). These results imply that decreased EGFR
protein stability contributes to decreases of this protein expression
in MUC1-suppressed cells, which leads to the suppression of
BPDE-induced activation of EGFR, Akt and ERK.
Suppressing MUC1 potentiates BPDE-induced
cytotoxicity
Having established that MUC1 is required for BPDE-induced
activation of EGFR-mediated Akt and ERK that protects
bronchial epithelial cells against BPDE’s cytotoxicity, we further
investigated if MUC1 plays a survival role when cells are exposed
to BPDE. BEAS-2B cells with stable MUC1 knockdown and
control cells transfected with negative shRNA were treated with
different concentrations of BPDE and cytotoxicity was detected by
LDH release and MTT assays. The results clearly show that
knockdown of MUC1 substantially potentiated BPDE-induced cell
death (Fig. 6C). Because in the MUC1 knockdown cells BPDE-
induced activation of EGFR-mediated Akt and ERK is suppressed
(Fig. 6A) and these pathways are required for cell survival during
BPDE challenge and BPDE induced transformation (Figs. 4, 5), it
is likely that MUC1 protects the cells from BPDE-induced
cytotoxicity and promotes cell transformation through potentiating
BPDE-induced activation of EGFR-mediated survival pathways.
Figure 3. Chronic BPDE exposure activates Akt and ERK
through EGFR in human bronchial epithelial cells. A, Induction
of MUC1 expression and EGFR-, Akt- and ERK-activation in HBEC-2 cells
by BPDE. Specifically, HBEC-2 cells were treated with the vehicle DMSO
or BPDE (0.1 mM) for the indicated weeks. Western blot was the same as
in A. b-Actin was detected as a loading control. B, Increased MUC1
expression and EGFR-, Akt- and ERK-activation in transformed HBEC-2
cells by BPDE. HBEC-2 cells were treated with BPDE (0.1 mM) for 12 wk
and then seeded in soft agar. Colonies were grown up for 3 wk in
transformed cells (TRANS). Wild-type (WT, exposed to sham) HBEC-2
cells were as a negative control. Expression of MUC1 and activation of
Akt and ERK were detected by Western blot in both WT and the
transfected cells. b-Actin was detected as a loading control.
doi:10.1371/journal.pone.0033846.g003
Figure 4. Blocking EGFR, Akt and ERK activation potentiates BPDE-induced cytotoxicity. BEAS-2B cells were pretreated with the indicated
inhibitors (LY (10 mM) for Akt, EGFRin (6 mM) for EGFR, U0126 (5 mM) for ERK, and SP (10 mM) for JNK) for 30 min followed by exposure to BPDE
(0.2 mM) for 48 hr. Cell viability was detected by LDH release and MTT assays. Data shown are mean 6 S.D; ** P,0.01, * P,0.05.
doi:10.1371/journal.pone.0033846.g004
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This study provides strong evidence supporting a cancer-
promoting role of MUC1 in CS-induced lung carcinogenesis:
MUC1 potentiated transformation of human bronchial cells
induced by the tobacco carcinogen BPDE; BPDE markedly
activated EGFR and its downstream pathways Akt and ERK, and
blocking these pathways significantly increased BPDE-induced
cytotoxicity and inhibited cell transformation; Suppression of
MUC1 expression destabilized EGFR protein and inhibited
BPDE-induced activation of EGFR, Akt and ERK, and
subsequently increased BPDE-induced cell death. These results
suggest that BPDE-induced transformation requires EGFR-
mediated Akt and ERK activation, and that MUC1 plays a lung
cancer-promoting role during lung cancer development, at least
partly through mediating carcinogen-induced activation of the
EGFR-mediated cell survival pathways that neutralize carcino-
gen’s cytotoxicity to facilitate cell transformation (Fig. 7).
Although the role of EGFR in lung cancer progression is well
known, whether and how EGFR contributes to lung epithelial cell
transformation is less clear. Specifically, whether EGFR is involved
in CS-induced transformation of lung epithelial cells has not been
reported. We found that CSE or the tobacco specific carcinogen
BPDE activate EGFR, and blocking EGFR signaling effectively
suppressed BPDE-induced transformation. These results clearly
place EGFR as a pivotal factor for lung cancer development at the
early time point. Our results further demonstrate that the EGFR-
mediated signaling pathways, particularly Akt, prevent cells from
BPDE’s cytotoxic effect and thereby potentiate bronchial epithelial
cell transformation. The ERK pathway, which contributed
moderately to cell survival, significantly potentiated cell transfor-
mation presumably through a mechanism other than cell survival.
In addition to cell survival, ERK is a major pathway for cell
proliferation [39]. Indeed, proliferation of mutated cells after
acquiring genetic and epigenetic modifications for malignant
transformation is vital for giving rise to tumors. Therefore, it
remains to be determined if ERK potentiates cell transformation
through stimulating transformed cell proliferation. Nevertheless,
our results suggest that activation of EGFR is a requisite for
tobacco carcinogens such as BPDE to induce malignant
transformation.
Although it is known that CS activates EGFR in lung epithelial
cells, the underlying mechanism is not well elucidated. It has been
shown that hydrogen peroxide-mediated stabilization of EGFR is
involved [40]. Here we show evidence that EGFR is activated by
CS specific carcinogen BPDE and MUC1 is required for the
activation. CS-induced MUC1 distribution is related to EGFR
activation in human bronchial epithelial cells [41]. Because EGFR
mRNA level was not affected by the expression of MUC1, it is
unlikely that MUC1 impacts EGFR at the level of transcription.
Instead, posttranslational modulation of EGFR is likely involved.
Indeed, reduced EGFR protein expression was observed in the
MUC1 knockdown cells. We clearly show that the stability of
EGFR protein is reduced in MUC1 knockdown cells, suggesting
that MUC1 potentiates BPDE-induced EGFR activation through
stabilization of the latter, similarly as in ligand-induced EGFR
activation in breast cancer cells [23]. Furthermore, although we
have not detected obvious induction of EGF or TGFa autocrine
from bronchial epithelial cells by BPDE (data not shown), whether
other EGFR ligands are involved in BPDE-induced and MUC1-
potentiated EGFR activation deserves further study.
It is well known that MUC1 expression in bronchial epithelial
cells is induced during inflammation [17], and chronic inflamma-
tion is associated with CS-induced lung carcinogenesis [42,43].
Figure 5. Suppression of EGFR, Akt and ERK activation inhibits BPDE-induced cell transformation. Graphical and quantitative
representation of colony formation in soft agar of BEAS-2B cells exposed to BPDE (0.1 mM) and/or the indicated inhibitors (EGFRin, LY, and U0126)
every two days for 1 week. Bars show the averages of colony numbers of 6 randomly selected fields. Data shown are mean 6 S.D; ** P,0.01.
doi:10.1371/journal.pone.0033846.g005
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expression during CS-induced chronic inflammation promotes
lung carcinogenesis. As MUC1 potentiates BPDE-induced activa-
tion of EGFR, it is likely that MUC1 contributes to lung cancer
development at least in part through EGFR-mediated cell survival
pathways such as Akt and ERK. While TNFa plays an important
role in inducing MUC1 expression in human lung epithelial cells
during acute inflammation as well as in lung infection [44,45], how
chronic inflammation enhances MUC1 expression has not been
determined. It is possible that consistent stimulation by TNFa
secreted from inflammatory cells keeps MUC1 expression in
bronchial and alveolar cells at high levels to promote lung cancer
development [46,47]. However, other mechanisms might underlie.
Indeed, in our in vitro assays with HBEC alone, MUC1 expression
was induced by BPDE or CSE. MUC1 retained at a high level
when cells were transformed, consistent with that MUC1 is
constitutively overexpressed in lung cancers. Thus, the mecha-
nisms by which MUC1 expression is activated by carcinogens and
retained at high levels in transformed cells deserve further
investigation. Nevertheless, our results suggest that MUC1
functions as a mediator that bridges CS-induced pulmonary
inflammation and lung cancer development by potentiating
EGFR-mediated survival signaling.
Eliminating transformed cells at the early stage of tumor
initiation would be a good chemoprevention approach against
cancer. In this regard, MUC1 and EGFR may serve as molecular
targets for lung cancer prevention. It has been shown that
Figure 6. MUC1 stabilizes EGFR, contributes to BPDE-induced EGFR, Akt and ERK activation in BEAS-2B cells and protects cells from
BPDE-induced cytotoxicity. A, MUC1 is required for BPDE-induced EGFR, Akt and ERK activation. Cells stably transfected with MUC1 shRNA or
negative control shRNA were treated with BPDE for the indicated time periods. Activation of each protein was detected with antibodies against the
phosphorylated form of the proteins. The phosphorylation sites of each protein are indicated. Total EGFR, Akt and ERK were also detected. b-Actin
was detected as an input control. B, Reduced EGFR expression in MUC1 Knockdown cells. Upper left, equal amounts of total RNA from the indicated
cells were detected for EGFR mRNA expression. b-Actin was detected as an input control. Upper right, Cells stably transfected with MUC1 shRNA or
negative control shRNA were treated with cycloheximide (CHX, 10 mM) for the indicated time periods. EGFR protein was detected by Western blot. b-
Actin was detected as an input control. Lower right, quantification of the results of Upper right. The intensity of the individual bands was quantified by
densitometry (NIH Image 1.62) and normalized to the corresponding input control (b-actin) bands. EGFR expression changes were calculated with the
control taken as 100%. C, BPDE-induced cytotoxicity is increased in MUC1 knockdown cells. BEAS-2B WT and MUC1 knockdown cells were treated
with the indicated concentrations of BPDE for 48 hr. Cell viability was detected by LDH release and MTT assays. Data shown are mean 6 S.D;
**P,0.01.
doi:10.1371/journal.pone.0033846.g006
Figure 7. A model of MUC1-mediated EGFR activation and
HBEC transformation. CS carcinogens such as BPDE trigger MUC1
expression in bronchial epithelial cells, facilitating EGFR-mediated cell
survival signaling via Akt and ERK activation. Akt and ERK protect cells
against DNA damage-mediated apoptosis to promote cell transforma-
tion, facilitating lung carcinogenesis.
doi:10.1371/journal.pone.0033846.g007
MUC1 Facilitates HBEC Cell Transformation
PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e33846targeting EGFR is able to reduce lung cancer burden in animal
studies [48]. Although targeting MUC1 and EGFR individually
have been proven to be effective in treating a portion of lung
cancer patients, chemoprevention against these two factors has not
been studied. In addition, because combined chemoprevention
targeting more than one oncogenic protein could potentiate the
cancer preventive activity and reduce toxicity, it would be
interesting to determine if a regime targeting both MUC1 and
EGFR achieves more effective prevention against lung cancer.
Supporting Information
Figure S1 Stable knockdown of MUC1 inhibits BPDE-
induced transformation in BEAS-2B cells. BEAS-2B cells
were infected with MUC1 shRNA or negative control shRNA and
stable clones were selected. Cell transformation and data analysis
are the same as described in Fig. 1 A and B. Insert, Confirmation
of MUC1 knockdown by Western blot.
(TIF)
Figure S2 Induction of MUC1 expression and EGFR-,
Akt- and ERK-activation in HBEC-2 cells by CSE
exposure. A, HBEC-2 cells were treated with CSE (10 mg/ml
TPM) for the indicated time periods. Activation of each protein
was detected with antibodies against the phosphorylated form of
the proteins. The phosphorylation sites of each protein were
indicated. Total EGFR was also detected. b-Actin was detected as
a loading control. B, HBEC-2 cells were treated with CSE (10 mg/
ml TPM) for the indicated weeks. Western blot was same as in A.
The expression of MUC1was also detected. b-Actin was detected
as a loading control.
(TIF)
Figure S3 Blocking protein degradation with MG132
and chloroquine eliminates EGFR expression difference
between the MUC1 knockdown and control cells. Beas-2B
cells stably transfected with MUC1 shRNA or negative control
(NC) shRNA were treated with lysosome inhibitor chloroquine
(CQ, 20 mM), proteasome inhibitor MG132 (10 mM), or both for
15 h. EGFR protein was detected by Western blot. b-Actin was
detected as an input control.
(TIF)
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